Twist Bioscience Corp (NASDAQ:TWST) CEO Emily M. Leproust has sold a portion of her company stock, according to a recent filing with the Securities and Exchange Commission. The transaction, which took place on April 2, 2024, involved the sale of 1,132 shares at a price of $32.736 per share, totaling over $37,057.
The sale was conducted as part of a tax withholding obligation related to the vesting of Restricted Stock Units. As stated in the footnotes of the filing, the shares were required to be sold to cover tax obligations and were not discretionary sales by Leproust. Following the transaction, Leproust still retains a significant stake in the company, with 514,149 shares of common stock.
Twist Bioscience, a company specializing in synthetic biology and genomics, has been a key player in the biological products industry. The CEO's recent stock transaction comes as part of standard practices within equity incentive plans, where companies often mandate "sell to cover" transactions to fulfill tax withholding requirements.
Investors and followers of Twist Bioscience can stay informed about the company's executive stock transactions, which are publicly disclosed for transparency and compliance purposes. Leproust's role as both a director and officer of the company, as well as her remaining substantial ownership, demonstrates her ongoing commitment to Twist Bioscience's success.
The filing also detailed various employee stock options held by Leproust, with different exercise prices and expiration dates, indicating her vested interest in the company's future performance. These stock options, which are rights to buy shares at a predetermined price, span expiration dates from 2025 to 2030 and have varying vesting schedules.
Twist Bioscience's stock performance and executive transactions are often closely watched by investors as indicators of the company's health and the confidence of its leadership in the company's direction and growth potential.
InvestingPro Insights
As Twist Bioscience Corp's CEO Emily M. Leproust manages her equity in the company through the recent sale of shares, investors may find additional context in the company's financial health and market performance through InvestingPro metrics and tips. Despite the transaction being a non-discretionary sale to cover tax obligations, understanding the broader financial landscape of TWST can offer insights into the company's stability and potential future performance.
InvestingPro Data reveals that Twist Bioscience holds a market capitalization of approximately $1.85 billion USD, with a substantial revenue growth of 21.58% over the last twelve months as of Q1 2024. This growth is bolstered by a quarterly increase of 31.81% in Q1 2024. The company's gross profit margin stands at a healthy 35.79%, indicating a strong ability to retain earnings after the cost of goods sold is accounted for.
However, the company's P/E ratio is currently negative at -8.98, reflecting that the market is anticipating future growth or the company is undervalued. This is further supported by the InvestingPro Tip that analysts do not expect Twist Bioscience to be profitable this year. Additionally, the company's stock price has experienced significant volatility, with a large price uptick of 78.38% over the last six months, yet a year-to-date price total return of -9.55%.
Investors should also note that Twist Bioscience does not pay dividends, which aligns with many growth-focused companies that prefer to reinvest earnings back into the company. Another key InvestingPro Tip highlights that Twist Bioscience holds more cash than debt on its balance sheet, which can be a positive sign of financial resilience and the ability to fund operations without relying heavily on external financing.
For those looking to delve deeper into Twist Bioscience's financials and market position, there are additional InvestingPro Tips available, offering comprehensive analysis and tailored insights. Interested readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, which includes access to these valuable resources. Remember, InvestingPro provides a total of 8 additional tips for Twist Bioscience, offering a more nuanced understanding of the company's financial health and stock performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.